cannabidiol-3-monomethyl ether has been researched along with masoprocol in 1 studies
| Studies (cannabidiol-3-monomethyl ether) | Trials (cannabidiol-3-monomethyl ether) | Recent Studies (post-2010) (cannabidiol-3-monomethyl ether) | Studies (masoprocol) | Trials (masoprocol) | Recent Studies (post-2010) (masoprocol) |
|---|---|---|---|---|---|
| 5 | 0 | 1 | 1,527 | 8 | 163 |
| Protein | Taxonomy | cannabidiol-3-monomethyl ether (IC50) | masoprocol (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 3.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 3.5 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeda, S; Usami, N; Watanabe, K; Yamamoto, I | 1 |
1 other study(ies) available for cannabidiol-3-monomethyl ether and masoprocol
| Article | Year |
|---|---|
Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor.
Topics: Animals; Cannabidiol; Dose-Response Relationship, Drug; Humans; Lipoxygenase Inhibitors; Masoprocol; Methylation; Molecular Structure; Structure-Activity Relationship | 2009 |